Sancho-Garnier H
Espace de prévention Epidaure, Montpellier, France.
Bull Cancer. 1995 Jul;82 Suppl 3:207s-212s.
Prevention envisions either a reduction in the incidence of a disease through direct action against its causes, or a reduction of the consequences of that disease (especially mortality), by action against the process leading to clinical expression of the underlying pathology. As in therapeutic medicine, preventive measures must be thoroughly evaluated for efficacy and secondary effects before they become standard recommendations. Two levels of evaluation can be identified: evaluation of feasibility, acceptability, involving quality control of the proposed programme, evaluation of results according to previously defined and quantified objectives. In order to demonstrate that the risk-benefit ratio of a preventive strategy is favorable, results in the intervention group must be compared with those in the control group, just as is done in therapeutic trials. Further more, prevention applies generally to healthy subject ie those not needing medical care and for whom, in the majority of cases, there will be no direct benefit. As a consequence, careful ethical consideration must be given to such programme. In particular, calculating the risk-benefit ratio must take into account the mental and social well being of people whose lives will be "medicalized" as a result of such intervention. Measurement of the consequences of such preventive actions on the life style and mental health of the population subjected to them necessitates the development of specific tools adapted to such situations. Research in methodology in this area is essential. If a population with almost 100% risk for a disease can be identified (genetic risk for example), aggressive preventive intervention can be limited to only that group. It must be emphasized that identification of subjects at risk, no matter how reliable, is not an end in itself. It is only justified, on a medical point of view, if we can offer these individuals a preventive programme with demonstrated benefit. The primacy of collective benefit over individual interest mandates that preventive intervention be based on voluntary informed consent of the target population. An alternative to individual consent could be, in some occasion, a "collective" consent.
预防旨在通过直接针对疾病病因采取行动来降低疾病发病率,或者通过针对导致潜在病理临床症状的过程采取行动来减轻疾病后果(尤其是死亡率)。与治疗医学一样,预防措施在成为标准建议之前,必须对其疗效和副作用进行全面评估。可以确定两个评估层面:可行性、可接受性评估,包括对拟议方案的质量控制;根据预先确定和量化的目标评估结果。为了证明预防策略的风险效益比是有利的,干预组的结果必须与对照组的结果进行比较,就像在治疗试验中那样。此外,预防通常适用于健康人群,即那些不需要医疗护理的人,而且在大多数情况下,他们不会直接受益。因此,必须对此类方案进行认真的伦理考量。特别是,计算风险效益比时必须考虑到那些因这种干预而生活将被“医学化”的人的心理和社会福祉。衡量此类预防行动对受其影响人群的生活方式和心理健康的后果,需要开发适用于此类情况的特定工具。这一领域的方法学研究至关重要。如果能够识别出患某种疾病风险几乎为100%的人群(例如遗传风险),积极的预防干预就可以仅限于该群体。必须强调的是,识别有风险的个体,无论多么可靠,其本身并不是目的。从医学角度来看,只有当我们能够为这些个体提供已证明有益的预防方案时,才是合理的。集体利益高于个人利益这一原则要求预防干预必须基于目标人群的自愿知情同意。在某些情况下,替代个人同意的方式可以是“集体”同意。